Data demonstrated that LCP-Tacro has a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf. LCP-Tacro also shows higher bioavailability by more than 40% compared to Prograf with improved pharmacokinetics and reduced variability (peak-to-trough ratio).
Flemming Oernskov, president and CEO of LifeCycle Pharma, said: “The results are a very important milestone for LCP and demonstrate LCP-Tacro’s potential advantages over Prograf. With these positive data we expect to initiate Phase III clinical studies in the second half of 2008. LCP-Tacro will be the first product that we expect to fully develop and commercialize ourselves in selected markets.”